Logo Florian Priese
Short overview

Prof. Dr. Florian Priese

Over 10 years of experience in quality management and process optimization in GMP production of solid and sterile drugs and medical devices.

Many years of experience in preparation and support of international authority audits as well as customer audits.

Profound knowledge of European and international GMP regulations.

Experienced leader with strong teamwork skills, high motivation and strong assertiveness.

Pragmatic approach and hands-on mentality.

Strategically oriented with excellent sense of business relevant aspects.

WORK EXPERIENCE
01/2022 – present

Healthcare Consultant

cgmp-solutions
Dessau-Roßlau

Global consultant for management, quality, operations, supply chain planning of solids and sterile dosage forms or medical devices

 

Projects and results:

CMO Manager and OPEX Expert, Pharmaceutical company
  • Optimization of CMO management regarding OTIF, quality KPIs and production readiness
  • Implementation of OEE measurement within operations
Head Drug Product, Pharmaceutical company CMO
  • Responsible for 4 aseptic filling lines and visual inspection with a team of 150 employees
  • Implementation of shop floor management, optimization maintenance strategy and batch record review process
Drug Product Expert, Pharmaceutical company CDMO
  • Head Production according AMWHV for aseptic production
  • Strategic CAPEX planning to uplift production capabilities
02/2019 – 12/2021

Senior Director Drug Product

IDT-Biologika GmbH
Dessau-Roßlau

Leading contract manufacturer in development and manufacture of vaccines and pharmaceuticals. Turnover >250 Mio. €, 1.500 Employees

 

Responsible:

  • Budget up to 25 Mio. € / team of 400 employees
  • Responsible for aseptic filling and inspection of pharmaceuticals and vaccines (filling in ampoules, vials and syringes, freeze-drying)
  • Continuous improvement of existing production processes
  • Manage relationships with health authorities, external customers and vendors

Results:

  • Reduction of reject batches by 70% due to process analysis and optimization
  • FTE neutral volume increase by 15% due to increased efficiency (introduction visual management, DMAIC for reduction technical stoppages, KATA)
  • Technical upgrade to state-of-the-art with CAPEX projects (volume 5 million p.a.) with minimum impact on production output
06/2018 – 01/2019

Head Process Unit, Member of Management Board

Aeropharm GmbH (Novartis)
Rudolstadt

Global developer and producer of respiratory medicines

 

Responsible:

  • Budget up to 15 Mio. € / team of 130 employees
  • Responsible for all manufacturing departments (bulk and packaging) of inhalation products (medical devices)
  • Restructuring of the production portfolio with two product launches

Results:

  • Successful completion of two FDA pre-approval inspections
  • Increased efficiency in production by reducing changeover times (SMED)
01/2017 – 05/2018

Head Operational Excellence, Member of Management Board

Aeropharm GmbH (Novartis)
Rudolstadt

Global developer and producer of respiratory medicines

  • Process optimization with Six Sigma & Lean Tools
  • Coordination and prioritization of improvement projects
  • Roll-out and training of Operational Excellence skills at the site

Results:

  • Successful Black Belt project, verified savings of 500,000 € p.a.
  • Train the Trainer training
  • Coaching of 2 Black and 6 Green Belt projects
  • Coordination and implementation of improvement projects with verified P&L impact of 1.5m € p.a.
02/2016 – 11/2017

Head Steriles

Aeropharm GmbH (Novartis)
Rudolstadt

Global developer and producer of respiratory medicines

 

Responsible:

  • Budget up to 3,5 Mio. € / team of 25 employees
  • Head of production according AMWHV §12
  • Ensuring aseptic GMP production of eye drops
  • Production, control and storage of medical products and qualification and process validation according to international law (GMP)

Results:

  • Quality improvement due to deep dive root cause investigations (no media fill and clean room monitoring issues)
  • OTIF increase from 60 to 95%
  • Improvement quality KPIs (on time completion deviation, CAPAs, CC) >90%
06/2014 – 01/2016

Senior Product Quality Manager

Salutas Pharma GmbH (Novartis)
Barleben, Germany

Generic pharmaceutical production and logistics of solid dosage forms

  • Galenic process development of solid dosage forms
  • Continued Process Verification with analysis of critical process parameters (CPP) and quality attributes (CQA)

Results:

  • Successful Green Belt project, verified savings of €1,000,000 p.a.
  • Reduction of rejected batches rate for two products by 70% through DMAIC projects
  • Optimization of project management for process validation (coordination between operations, quality, supply chain) with reduction of lead time by 70%
  • Implementation of online PAT (Process Analytical Technology) tool for process monitoring
12/2013 – 05/2014

Compliance Officer Pharma production

Boehringer Ingelheim Pharma GmbH & Co. KG
Ingelheim am Rhein, Germany

Global research-based pharmaceutical company

  • Assurance of GMP production solid dosage forms, Deviation and CAPA management, preparation and follow up FDA audit
08/2012 – 11/2013

Process Engineer and Deputy Steriles

Aeropharm GmbH (Novartis)
Rudolstadt, Germany

Global developer and producer of respiratory medicines

  • Aseptic ophthalmic production
  • Head of production according AMWHV §12
  • Ensuring qualification and validation status
  • Process analysis and optimization
10/2007 – 01/2010

Product Manger

Salutas Pharma GmbH (Sandoz)
  • Process optimization (yield improvement) and technology transfer solids
PUBLICATIONS

Inline-Messung von Schichtdicke, Agglomeratanteil und Sprühtrocknung beim Pelletcoating in der Wirbelschicht – Einsatz einer Inline-Partikelsonde als PAT-Instrument zur Echtzeit Überwachung
(D. Petrak, G. Eckardt, S. Dietrich, M. Köhler, B. Wolf, F. Priese; M. Jacobs, Pharmazeutische Industrie 80 2018, Nr. 2, S. 262-270)

In-line particle size measurement and agglomeration detection of pellet fluidized bed coating by Spatial Filter Velocimetry
(D. Wiegel, G. Eckardt, F. Priese, B. Wolf: Powder Technology 301 2016, S. 261-267)

Comparison of film coated retarded release pellets manufactured by layering technique or by bed rotor pelletization
(F. Priese; T. Frisch, B. Wolf: Pharmaceutical Development and Technology 20 2015, Nr. 4, S. 417-425)

Optimization of pellet coating by design of experiment and population balance
(F. Priese; B. Wolf: Powder Technology 241 2013, S. 149-157)

Education

02/2010 – 06/2014
Otto-von-Guericke University / Magdeburg, Germany
Thermal Process Engineering

PhD thesis: Development of coated pellets with functional layers using discontinuous fluidized bed technology

10/2003 – 09/2007
University of Applied Sciences Magdeburg-Stendal / Magdeburg, Germany
Pharmaceutical Engineering

Diploma (Master) thesis: Development and validation of analytical methods

08/1993 – 06/2002
Abitur (university entrance level exams) / Gymnasium Carolinum (secondary school) / Bernburg, Germany

menucross-circle